AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

NCT07021950 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Ivonescimab

Interventions

DRUG: AK112
DRUG: FOLFIRI
DRUG: Bevacizumab

Sponsor

Sun Yat-sen University